PRCT (PROCEPT BioRobotics) Change In Receivables: $-18.1 Mil (TTM As of Mar. 2026)


PRCT PROCEPT BioRobotics Corp PRCT
70 GF Score
Price $20.90
GF Value $93.13
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PROCEPT BioRobotics Change In Receivables?

PROCEPT BioRobotics PRCT +5.77% 70 Change In Receivables is $-18.1 Mil as of Mar. 2026. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $93.13 (Significantly Undervalued). The stock has 2 warning signs investors should review.

PROCEPT BioRobotics's change in receivables for the quarter that ended in Mar. 2026 was $-13.3 Mil. It means PROCEPT BioRobotics's Accounts Receivable increased by $13.3 Mil from Dec. 2025 to Mar. 2026 .

PROCEPT BioRobotics's change in receivables for the fiscal year that ended in Dec. 2025 was $-0.9 Mil. It means PROCEPT BioRobotics's Accounts Receivable increased by $0.9 Mil from Dec. 2024 to Dec. 2025 .

PROCEPT BioRobotics's Accounts Receivable for the quarter that ended in Mar. 2026 was $96.4 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. PROCEPT BioRobotics's Days Sales Outstanding for the three months ended in Mar. 2026 was 105.80.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PROCEPT BioRobotics's liquidation value for the three months ended in Mar. 2026 was $217.3 Mil.

PROCEPT BioRobotics  (NAS:PRCT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

PROCEPT BioRobotics's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=96.388/83.132*91
=105.80

2. In Ben Graham's calculation of liquidation value, PROCEPT BioRobotics's accounts receivable are only considered to be worth 75% of book value:

PROCEPT BioRobotics's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=245.641-139.395+0.75 * 96.388+0.5 * 77.536
=217.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROCEPT BioRobotics Change In Receivables Related Terms

PROCEPT BioRobotics Change In Receivables Historical Data

* Premium members only.

The historical data trend for PROCEPT BioRobotics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROCEPT BioRobotics Change In Receivables Chart

PROCEPT BioRobotics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial -2.91 -10.81 -33.10 -35.96 -0.90

PROCEPT BioRobotics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.93 -2.71 -4.35 2.23 -13.32
PRCT
70GF Score
PROCEPT BioRobotics Corp PRCT
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PROCEPT BioRobotics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-18.1 Mil mean?
PROCEPT BioRobotics (PRCT) has a Change In Receivables of $-18.1 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PROCEPT BioRobotics and its competitors.
Is PROCEPT BioRobotics' Change In Receivables too high?
PROCEPT BioRobotics' current Change In Receivables is $-18.1 Mil. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Change In Receivables compare to ENOV and INSP?
PROCEPT BioRobotics' Change In Receivables of $-18.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PROCEPT BioRobotics and its competitors. PROCEPT BioRobotics's current Change In Receivables is $-18.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $93.13, compared to a current price of $20.90 — trading 77.6% below its estimated fair value. The current Change In Receivables is $-18.1 Mil. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Change In Receivables is $-18.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of $20.90 is trading 77.6% below its estimated GF Value™ of $93.13. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for PRCT:

  • Change In Receivables: $-18.1 Mil
  • GF Value™: $93.13 vs. price of $20.90 (77.6% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROCEPT BioRobotics Business Description

Other Exchanges PRCT:Mexico
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score

Get the complete analysis for PRCT

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.90
Price
$93.13
GF Value